RWS,
I apologize for the delay in posting a response to the press release that you posted in reply to me. I wanted to get more data on this technology (that was "acquired from Astral, Inc.")
Below is data that they published with a link below it. If you click on my username and see what I have posted about the Avian flu on the "biotech news" thread, in addition to what others have posted there and on the Avian stocks thread, it is an eye opener into the importance and potential urgency of this technology being developed, imho! Shawn
1: J Clin Invest. 2002 Oct;110(8):1175-84. Related Articles, Links
Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination.
Wang L, Smith D, Bot S, Dellamary L, Bloom A, Bot A.
Department of Immunology, Astral Inc. of Alliance Pharmaceutical Corporation, 3040 Science Park Road, San Diego, California 92121, USA.
The adaptive immune response is triggered by recognition of T and B cell epitopes and is influenced by "danger" motifs that act via innate immune receptors. This study shows that motifs associated with noncoding RNA are essential features in the immune response reminiscent of viral infection, mediating rapid induction of proinflammatory chemokine expression, recruitment and activation of antigen-presenting cells, modulation of regulatory cytokines, subsequent differentiation of Th1 cells, isotype switching, and stimulation of cross-priming. The heterogeneity of RNA-associated motifs results in differential binding to cellular receptors, and specifically impacts the immune profile. Naturally occurring double-stranded RNA (dsRNA) triggered activation of dendritic cells and enhancement of specific immunity, similar to selected synthetic dsRNA motifs. Based on the ability of specific RNA motifs to block tolerance induction and effectively organize the immune defense during viral infection, we conclude that such RNA species are potent danger motifs. We also demonstrate the feasibility of using selected RNA motifs as adjuvants in the context of novel aerosol carriers for optimizing the immune response to subunit vaccines. In conclusion, RNA-associated motifs produced during viral infection bridge the early response with the late adaptive phase, regulating the activation and differentiation of antigen-specific B and T cells, in addition to a short-term impact on innate immunity.
MeSH Terms:
Adaptation, Physiological
Adjuvants, Immunologic/pharmacology
Animals
Antibodies, Viral/biosynthesis
Antigens, Viral/administration & dosage
Female
Mice
Mice, Inbred BALB C
Mice, Inbred C3H
Mice, Inbred C57BL
Mice, Knockout
RNA, Untranslated/genetics*
RNA, Untranslated/immunology*
RNA, Untranslated/pharmacology
Rats
Rats, Sprague-Dawley
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Vaccination
Viral Vaccines/administration & dosage
Virus Diseases/immunology
Substances:
Adjuvants, Immunologic
Antibodies, Viral
Antigens, Viral
RNA, Untranslated
Viral Vaccines
Grant Support:
1R21 AI 47014/AI/NIAID
PMID: 12393853 [PubMed - indexed for MEDLINE]
ncbi.nlm.nih.gov |
